Stagezero Life Sciences (SZLSF) Stock Price, News & Analysis

Company Overview

StageZero Life Sciences (OTCMKTS:SZLSF) is a molecular diagnostics company headquartered in Vancouver, British Columbia, that develops and commercializes precision oncology assays for the early detection of solid tumor cancers. The company’s core business revolves around its proprietary OncoSignature™ and OncoScreen™ platforms, which analyze gene expression patterns in blood or tissue samples to identify cancer at its earliest stages. These platforms are designed to deliver reliable, non‐invasive diagnostics that can be deployed in clinical laboratory settings or through strategic partnerships with medical centers and telehealth providers.

StageZero offers a suite of tests targeting a range of cancer types, including breast, lung, colorectal and prostate cancers. By integrating advanced bioinformatics and machine‐learning algorithms, the company’s assays aim to improve diagnostic accuracy and reduce the need for invasive biopsies. In addition to assay development, StageZero provides supporting software tools for data interpretation and reporting, enabling clinicians to make informed treatment decisions based on molecular insights.

Founded in 2017, StageZero has built its research and development operations in British Columbia, supported by satellite facilities in Europe and Asia. The company has forged collaborations with academic institutions and contract research organizations to advance validation studies and expand its test menu. Commercial activities initially focused on the Canadian market, with subsequent rollouts in the United States and selected international territories through distribution agreements and laboratory partnerships.

StageZero’s leadership team is led by Chief Executive Officer Dave MacDonald, who brings more than three decades of experience in the life sciences industry. The executive bench includes specialists in molecular diagnostics, regulatory affairs and commercial development, all working to position the company as a leader in early‐stage cancer detection. Moving forward, StageZero seeks to broaden its clinical offerings, enhance its technology pipeline and establish itself as a go‐to provider of precision oncology solutions worldwide.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.00 to $0.03
• 52-Week Range: $0.00 to $1.00
• Volume: N/A
• Average Volume: 3,216 shs
• Market Capitalization: $2.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SZLSF Stock Analysis - Frequently Asked Questions

How have SZLSF shares performed this year?

Stagezero Life Sciences' stock was trading at $0.0016 on January 1st, 2025. Since then, SZLSF stock has increased by 1,325.0% and is now trading at $0.0228.

How do I buy shares of Stagezero Life Sciences?

Shares of SZLSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SZLSF
• CIK: 1454263
• Web: www.stagezerolifesciences.com
• Phone: (855) 420-7140
• Fax: 905-209-2031
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.80 million
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 123,530,000
• Free Float: 120,395,000
• Market Cap: $2.82 million
• Optionable: Not Optionable
• Beta: -0.15